X0306 4 2020-02-20 true 0001557883 Dermira, Inc. DERM 0001208907 WIGGANS THOMAS G C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 true true false false CEO & Chairman of the Board Common Stock 2020-02-05 5 G false E 27000.00 0.00 D 49963.00 D Common Stock 2020-02-20 4 D false 49963.00 18.75 D 0.00 D Common Stock 2020-02-20 4 D false 180985.00 18.75 D 0.00 I By the Wiggans Living Trust dated 5/14/02 Stock Options (Right to buy) 0.986 2020-02-20 4 D false 164642.00 D 2021-10-03 Common Stock 164642.00 0.00 D Stock Options (Right to buy) 1.218 2020-02-20 4 D false 115022.00 D 2023-01-03 Common Stock 115022.00 0.00 D Stock Options (Right to buy) 1.218 2020-02-20 4 D false 64327.00 D 2023-01-03 Common Stock 64327.00 0.00 D Employee Stock Options (Right to buy) 1.74 2020-02-20 4 D false 98430.00 D 2023-07-10 Common Stock 98430.00 0.00 D Stock Options (Right to buy) 16.00 2020-02-20 4 D false 355170.00 D 2024-10-01 Common Stock 355170.00 0.00 D Stock Options (Right to buy) 26.37 2020-02-20 4 D false 180000.00 D 2026-02-04 Common Stock 180000.00 0.00 D Employee Stock Options (Right to buy) 33.84 2020-02-20 4 D false 180000.00 D 2027-02-16 Common Stock 180000.00 0.00 D Employee Stock Options (Right to buy) 28.25 2020-02-20 4 D false 150000.00 D 2028-02-14 Common Stock 150000.00 0.00 D Employee Stock Options (Right to buy) 7.42 2020-02-20 4 D false 300000.00 D 2029-02-11 Common Stock 300000.00 0.00 D Restricted Stock Unit 2020-02-20 4 D false 9000.00 D Common Stock 9000.00 0.00 D Restricted Stock Unit 2020-02-20 4 D false 15000.00 D Common Stock 15000.00 0.00 D Restricted Stock Unit 2020-02-20 4 D false 50000.00 D Common Stock 50000.00 0.00 D Includes 1,023 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan. Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. The Reporting Person is a Co-Trustee. Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. /s/ Andrew L Guggenhime as attorney-in-fact 2020-02-24